Irreversible inhibitors of the erbB family of protein tyrosine kinases

Pharmacology and Therapeutics

Volumn 93, Issue 2-3, 2002, Pages 253-261

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anilinoquinazoline; Cancer chemotherapy; Cysteine alkylation; EGFR; ErbB2; Tyrosine kinase inhibitor

Indexed keywords

ACRYLAMIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; AMIDE; ANILINE; ANTINEOPLASTIC AGENT; CANERTINIB; PELITINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; BINDING SITE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY; REVIEW;

ENZYME INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035990923     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00194-8     Document Type: Conference Paper

References (41)

1. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
2. ZD1839 ('Iressa') as an anticancer agent
3. Chemical inhibitors of protein kinases
4. Tyrosine kinase inhibitors. 8. An unusually steep structure activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor
5. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
6. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
7. Assessment of HER2 status in breast cancer: Why, when and how?
8. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
9. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
10. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
11. A Phase 1 and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors
12. Evidence for receptor enhanced chemosensitivity in combinations of the cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033
13. Optimizing EGFR and erbB-2 tyrosine kinase inhibition: Structure activity relationship studies around the core 6-furanyl quinazoline template
14. The type I growth factor receptor family: New ligands and receptors and their role in breast cancer
15. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
16. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
17. The EGF receptor family as targets for cancer therapy
18. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
19. The erbB signalling network: Receptor heterodimerization in development and cancer
20. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazinoquinazolines as EGFR inhibitors: Synthesis, biological evaluation and modelling of the mode of binding
21. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
22. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-(phenylmethyl)amino- and 4-phenylaminoquinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor
23. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors
24. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
25. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
26. A Phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors
27. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases
28. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
29. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
30. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
31. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)-quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
32. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
33. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]-pyrido[4,3-d]pyrimidines; A new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
34. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]-pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
35. Combinatorial chemoprevention of intestinal neoplasia
36. 4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase
37. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (her-2) tyrosine kinases with enhanced antitumor activity
38. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor
39. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors
40. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor